Compare Equitable Holdings Inc. Common Stock (EQH) vs 10X Genomics Inc (TXG) Price & Performance

Equitable Holdings (EQH) trades at $53.12, down 0.75% on the day, with strong analyst support (95% buy ratings) and a $64.71 consensus price target suggesting 22% upside. Recent quarterly earnings have consistently beaten expectations, though the company reported a net loss of $1.38B for 2025. The planned merger with Corebridge and expansion into fee-based businesses are key growth drivers, while high debt-to-asset ratio of 2.07 presents financial risk.

EQH shows mixed fundamentals with positive earnings momentum but negative profitability metrics. The stock offers significant upside potential based on analyst targets, supported by strategic initiatives and dividend appeal. Key risks include execution of the Corebridge merger, persistent net losses, and high leverage. Investors should weigh strong analyst conviction against fundamental weaknesses.

TXG trades at $71.79, down 4.52% on the day, amid a bearish technical signal. The company shows improving fundamentals with revenue of $642.82M in 2025 and a narrowing net loss of -$43.54M. Recent news highlights strong demand for its Atera spatial biology platform and a patent victory, though insider selling and high valuation ratios like a P/S of 15.13 and EV/EBITDA of 241.6 present concerns.

The outlook is mixed; analyst consensus is a Buy with a $83.30 price target, but execution risks on Atera delivery and sustained profitability remain key. Upside depends on commercial success of new platforms, while downside risks include competitive pressures and failure to achieve positive earnings.